Discovery of endocannabinoid gene mutation leads to identification of new, rare pediatric neurological disease miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
La Jolla, California (PRWEB) February 08, 2022 New research from Sanford Burnham Prebys has revealed significant molecular differences between the breast
E-Mail
Credit: Sanford Burnham Prebys
LA JOLLA, CALIF. - May 19, 2021 - A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to help avoid disease relapse or progression of endocrine-sensitive disease.
The study was published in the journal
Nature Communications.
Nearly 80% of breast tumors are estrogen receptor (ER)-positive. For decades, these tumors have been treated with anti-estrogen (endocrine) therapies to lower estrogen levels and help slow the cancer s growth. About 20% of breast cancers are also HER2-positive at diagnosis, and these tumors tend to be more aggressive and fast-growing, as HER2 is a receptor that when active, promotes the rapid growth of breast cancer cel